Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 10

1.

Differential pricing for pharmaceuticals: reconciling access, R&D and patents.

Danzon PM, Towse A.

Int J Health Care Finance Econ. 2003 Sep;3(3):183-205. Review.

PMID:
14625999
2.

Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

Jarosławski S, Toumi M.

BMC Health Serv Res. 2011 Oct 8;11:259. doi: 10.1186/1472-6963-11-259. Review.

3.

Comparing patient access to pharmaceuticals in the UK and US.

Cohen J, Cairns C, Paquette C, Faden L.

Appl Health Econ Health Policy. 2006;5(3):177-87.

PMID:
17132032
4.

Patient access to pharmaceuticals: an international comparison.

Cohen J, Faden L, Predaris S, Young B.

Eur J Health Econ. 2007 Sep;8(3):253-66. Epub 2007 Feb 6.

PMID:
17279403
5.

Pharmaceuticals and the health of the public: use, safety, cost, access, ethics, and quality.

Zito JM.

Med Care. 2012 Nov;50(11):907-9. doi: 10.1097/MLR.0b013e3182733b57. No abstract available.

PMID:
23047777
7.

Patents or patients? Global access to pharmaceuticals and social justice.

de Wildt G, Khoon CC.

Med Confl Surviv. 2008 Apr-Jun;24 Suppl 1:S52-61. doi: 10.1080/13623690801957380.

PMID:
18771195
8.

Quantitative assessment of TRPM5-dependent oral aversiveness of pharmaceuticals using a mouse brief-access taste aversion assay.

Devantier HR, Long DJ, Brennan FX, Carlucci SA, Hendrix C, Bryant RW, Salemme FR, Palmer RK.

Behav Pharmacol. 2008 Oct;19(7):673-82. doi: 10.1097/FBP.0b013e3283123cd6.

PMID:
18797244
9.

Balancing access to pharmaceuticals with patent rights.

Nicol D.

Monash Bioeth Rev. 2003 Apr;22(2):50-62.

PMID:
15069957
10.

Supplemental Content

Support Center